Nathalie Cambier

No ORCID on file · 2 papers in corpus

article 2023

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

·doi:10.1016/s0140-6736(22)02036-0

BackgroundJanus kinase (JAK) inhibitors approved for myelofibrosis provide spleen and symptom improvements but do not meaningfully improve anaemia. Momelotinib, a first-in-class inhibitor of activin A receptor type 1 as well as JAK1 and JAK…

article 1994

Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases

·doi:10.1111/j.1365-2141.1994.tb04895.x

Twenty patients with myelodysplastic syndromes (MDS) and (i) platelets < 50 x 10(9)/l and (ii) bone marrow blasts < or = 10% were treated with androgen therapy (fluoxymesterone at 1 mg/kg/d: seven patients; danazol at 600 mg/d: 13 patients)…